Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 11 Nov 2026
Standard addition

Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib.

A rapid genetic test helps identify which breast cancer patients may benefit from a specific targeted therapy.

The study validated a rapid assay for PIK3CA, AKT1, and PTEN alterations linked to capivasertib treatment. The assay showed 89.2% overall agreement with FoundationOne CDx and identified a subgroup with progression-free survival benefit from capivasertib plus fulvestrant.

What the study was

Study design
Analytical validation and retrospective clinical validation study
Population
429 residual tumor samples from the phase III CAPItello-291 breast cancer trial
Sample size
429
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
Translational oncology

Why it surfaced

The assay has both analytical and trial-linked clinical validation, though its false-negative rate for complex PTEN variants warrants caution

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.